Table 2 Outcomes according to VMB composition at 12- and 24-month follow-up at genus and species level.

From: The vaginal microbiota associates with the regression of untreated cervical intraepithelial neoplasia 2 lesions

Genus level

 

Regression

Non-regression

Total

Unadjusted OR, 95% CI (p-value)

Adjusted OR, 95% CI (p-value)a

Follow-up 0–12 months

     

 Lactobacillus-dominant

33/57 (57.9%)

24/57 (42.1%)

57/87 (65.5%)

REF

REF

 Lactobacillus spp.-depleted

9/30 (30.0%)

21/30 (70.0%)

30/87 (34.5%)

3.21, 1.32–8.22 (0.015)

3.56, 1.31–9.60 (0.012)

 Total

42/87 (48.3%)

45/87 (51.7%)

87/87 (100%)

  

Follow-up 0–24 months

 Lactobacillus-dominant

45/57 (78.9%)

12/57 (21.1%)

57/87 (65.5%)

REF

REF

 Lactobacillus spp.-depleted

18/30 (60.0%)

12/30 (40.0%)

30/87 (34.5%)

2.50, 0.95–6.59 (0.064)

2.85, 1.03–7.92 (0.045)

 Total

63/87 (72.4%)

24/87 (27.6%)

87/87 (100%)

  

Follow-up 12–24 months

 Lactobacillus-dominant

15/22 (68.2%)

7/22 (31.8%)

22/35 (88.0%)

REF

REF

 Lactobacillus spp.-depleted

6/13 (46.2%)

7/13 (53.8%)

13/35 (22.0%)

2.50, 0.61–10.26 (0.203)

3.06, 0.54–17.14 (0.202)

 Total

21/35 (60.0%)

14/35 (40.0%)

35/35 (100%)

  

Species level

 

Regression

Non-regression

Total

Unadjusted OR, 95% CI (p-value) 

Adjusted OR, 95% CI (p-value)a

Follow-up 0–12 months

     

 CST I

13/21 (59.1%)

8/21 (40.9%)

21/87 (24.1%)

REF

REF

 CST III

20/36 (55.6%)

16/36 (44.4%)

36/87 (41.4%)

1.30, 0.43–3.90 (0.640)

1.14, 0.32–4.05 (0.838)

 CST IV

9/30 (31.0%)

21/30 (69.0%)

30/87 (34.5%)

3.79, 1.17–12.30 (0.026)

3.85, 1.10–13.42, (0.035)

 Total

42/87 (48.3%)

45/87 (51.7%)

87/87 (100%)

  

Follow-up 0–24 months

 CST I

18/21 (85.7%)

3/21 (14.3%)

21/87 (24.1%)

REF

REF

 CST III

27/36 (75.0%)

9/36 (25.0%)

36/87 (41.4%)

2.00, 0.47–8.41 (0.344)

1.86, 0.39–8.81 (0.432)

 CST IV

18/30 (60.0%)

12/30 (40.0%)

30/87 (34.5%)

4.00, 0.96–16.61 (0.056)

4.25, 0.98–18.50 (0.054)

 Total

63/87 (72.4%)

24/87 (27.6%)

87/87 (100%)

  

Follow-up 12–24 months

 CST I

4/5 (80.0%)

1/5 (20.0%)

5/35 (14.3%)

REF

REF

 CST III

11/16 (68.8%)

5/16 (31.2%)

16/35 (45.7%)

1.82, 0.15–20.71 (0.630)

1.30, 0.06–27.07 (0.865)

 CST IV

6/13 (46.2%)

7/13 (53.8%)

13/35 (37.1%)

4.67, 0.40–53.95 (0.217)

4.94, 0.26–94.86 (0.29)

 CST V

0/1 (0%)

1/1 (100%)

1/35 (2.9%)

NAb

NAb

 Total

21/35 (60.0%)

14/35 (40.0%)

35/35 (100%)

  
  1. Odds ratios (OR) are represented as unadjusted and adjusted for patient age, ethnicity, smoking, douching, contraception, HPV16 and 18 positivity, with p-values represented are two-tailed Fisher’s exact (if <5 observations in any group) and χ2 tests (where >5 observations in every group).
  2. aOR adjusted odds ratio, CI confidence Interval, CST community state type, CST I (Lactobacillus crispatus-dominant), CST III (Lactobacillus iners-dominant), CST IV (Lactobacillus spp.-depleted, high diversity), CST V (Lactobacillus jensenii), NA not applicable, OR odds ratio, REF reference population.
  3. aAdjusted odds ratio and 95% confidence intervals were calculated using Lactobacillus-dominant (genus) or CST I (species) as a reference group and adjusted for patient age, ethnicity, smoking, douching, contraception, HPV16 and 18 positivity.
  4. bIt was not possible to compute the OR, 95% CI and p-value for CST V compared to CST I.
Back to article page